Re-differentiating therapy of radioiodine-refractory differentiated thyroid cancer

doi:10.3969/j.issn.1007-3969.2016.01.006

Abstract

Abstract: Clinical management of radioiodine-refractory differentiated thyroid cancer (RR-DTC) is extremely difficult. Re-differentiation compounds, such as retinoids, peroxisome proliferator-activated receptor (PPAR) agonists, DNA methyltransferase inhibitors and histone deacetylase inhibitors, have been used in trials to increase iodine uptake in RR-DTC. However, data on these drugs failed to meet the initial high expectations. In recent years, targeted agents have been increasingly used in pre-clinical and clinical studies to induce re-differentiation and mediate ¹³¹I therapy, and the outcomes are encouraging.

Key words: Thyroid cancer, Re-differentiating therapy, Targeted agents, ¹³¹I

CHENG Lingxiao, CHEN Libo. Re-differentiating therapy of radioiodine-refractory differentiated thyroid cancer[J]. China Oncology, 2016, 26(1): 35-42.

[1]	CHEN Guo , HAN Pengli , CHEN Keru , LI Mingchuang , ZHANG Qingsong , CHEN Zheng , DONG Hanhua , QIAN Yuejun , LÜ Jing . Molecular mechanism of miR-19b-3p regulating apoptosis of medullary thyroid cancer cells by targeting MTUS1 [J]. China Oncology, 2021, 31(5): 390-396.
[2]	YUAN Hao , JIANG Xiaofei , YOU Qinghua , ZHU Hongbo , YE Huiying , WU Wen , QIAN Fengyuan , ZHONG Ming , LI Yongping . Clinical application of fine needle puncture Diff-Quik staining for the differentiation and protection of parathyroid glands in thyroid carcinoma surgery [J]. China Oncology, 2021, 31(4): 302-307.
[3]	WU Yuanyuan , WANG Jun , LIU Qinjiang , ZHANG Ming . Analysis of prognostic factors and treatment strategies of anaplastic thyroid carcinoma [J]. China Oncology, 2021, 31(3): 212-220.
[4]	WU Hongwen, MEI Yan, WANG Qiao, YUAN Jia, ZHAO Liwei. The clinical value of serum MIP-1α and S-TK1 in the evaluation of postoperative radioactive ¹³¹ I treatment for thyroid carcinoma [J]. China Oncology, 2021, 31(11): 1088-1095.
[5]	LI Min, WEN Peng, QIAN Qiuqin, QIN Ang, ZENG Li, SHI Feng. Clinical study of iodine-125 seeds implantation in the treatment of lymph node metastasis of radioactive iodine- refractory differentiated thyroid cancer [J]. China Oncology, 2020, 30(2): 122-127.
[6]	MU Zhuanzhuan , LI Zheng , ZHANG Xin , LIN Yansong . The effect of empiric ¹³¹ I therapy in papillary thyroid cancer patients with pulmonary metastasis [J]. China Oncology, 2020, 30(12): 991-995.
[7]	REN Junling , CHEN Bin , TANG Xiaolei . Research on the correlation between BMI and pathologic factors of papillary thyroid carcinoma [J]. China Oncology, 2020, 30(12): 1041-1045.
[8]	YANG Ke, ZHENG Rong, LIN Yansong. The interpretation of management guidelines for children with thyroid nodules and differentiated thyroid cancer: radioactive iodine therapy and new progress [J]. China Oncology, 2019, 29(6): 401-411.
[9]	ZHANG Liyang, LIU Chunhao, CAO Yue, LIU Hongfeng, GAO Weisheng, LI Xiaoyi. Experiences of 125 cases of re-operated persistent/recurrent differentiated thyroid cancer [J]. China Oncology, 2019, 29(6): 412-417.
[10]	GAO Luying, LIN Yansong, JIANG Yuxin, LI Jianchu, LI Hui, ZHANG Bo, LIU Ruyu, XI Xuehua, GAO Qiong, WANG Ying, ZHAO Ruina. Evaluation of short-term efficacy of apatinib using cervical ultrasound and thyroglobulin in the treatment of progressive radioactive iodine-refractory differentiated thyroid cancer [J]. China Oncology, 2019, 29(6): 418-422.
[11]	LU Chenghui, LI Jiao, LIU Xinfeng, WANG Guoqiang, WANG Zenghua, WANG Xufu. Clinical outcome after ¹³¹I treatment in differentiated thyroid cancer with negative stimulated thyroglobulin and lymph node metastasis [J]. China Oncology, 2019, 29(6): 429-433.
[12]	ZHANG Na, LIN Yansong, LIANG Jun. The clinical significance of thyroglobulin antibody measurement in 131I therapy of differentiated thyroid carcinoma [J]. China Oncology, 2019, 29(6): 452-456.
[13]	CHEN Junhui, ZHANG Man, LIU Shuipeng, MA Lin, LIU Yang, LI Xiaosong, MENG Jian, LI Jie, ZHANG Shuhua. The research on risk prediction of thyroid cancer based on ultrasonic characteristic multivariate logistic regression coefficient β composite score method [J]. China Oncology, 2019, 29(4): 289-293.
[14]	SONG Juanjuan, LIU Yanqing, LIN Yansong. Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose ¹³¹I therapy [J]. China Oncology, 2019, 29(3): 207-211.
[15]	CAO Yiming, ZHU Yongxue. Screening of aberrant DNA methylation in papillary thyroid cancer [J]. China Oncology, 2019, 29(10): 780-787.

Re-differentiating therapy of radioiodine-refractory differentiated thyroid cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments